Intelligent Bio Solutions Expands Presence in the UK Retail Sector With Major Account Acquisitions
Intelligent Bio Solutions Expands Presence in the UK Retail Sector With Major Account Acquisitions
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the expansion of its customer network within the UK retail sector. This includes the adoption of INBS' Intelligent Fingerprinting Drug Screening System by three prominent UK retailers, among the largest and most recognized in the country.
2024年6月27日,紐約,環球新聞——智能生物解決方案公司(Intelligent Bio Solutions Inc.) (納斯達克: INBS) (以下簡稱"INBS"或"公司"),一家提供智能、快速、非侵入性測試解決方案的醫療科技公司,今天宣佈其在英國零售業內的客戶網絡擴大。其中包括三家英國知名的零售商採用 INBS 的智能指紋毒品篩查系統,這些零售商是該國最大、最知名的零售商之一。
The recently secured accounts employ over 55,000 individuals and include a British multinational retailer specializing in clothing, footwear, and accessories, a major UK-based kitchen retailer and manufacturer, and a British retail group specializing in sports and leisure clothing, footwear, and equipment. Two retailers have transitioned from traditional third-party saliva testing to INBS's fingerprint drug screening technology. The switch to a more streamlined, hygienic, and less invasive testing methodology has addressed business and policy alignment issues and previous testing inefficiencies, facilitating smoother processes that enable larger testing volumes.
最近獲得的帳户共僱用了55,000名員工,包括一家專門從事服裝、鞋類和配件的英國跨國零售商,一家主要位於英國的廚房零售商和製造商,以及一家專門從事體育休閒服裝、鞋類和裝備的英國零售集團。兩家零售商已從傳統的第三方唾液測試轉向了 INBS 的指紋毒品篩查技術。更輕鬆、更衛生、更少侵入性的測試方法解決了業務和政策對齊問題以及之前測試效率低下的問題,促進了更平穩的流程,使測試容量更大。
Doug Heath, Vice president of Global Sales at INBS, commented, "Our reach continues to extend into new sectors, indicating a demand for drug testing beyond just safety-critical industries. We're seeing more businesses taking proactive measures to ensure workplace safety and protect their reputation as responsible employers. We are very pleased to welcome these prominent retail partners into our growing network."
INBS 的全球銷售副總裁Doug Heath表示:"我們的業務範圍繼續擴展到新的領域,這表明除了關係到安全的行業外,對毒品測試的需求正在增加。我們看到越來越多的企業採取積極措施確保工作場所的安全,並保護自己作爲負責任的僱主的聲譽。我們非常高興歡迎這些知名零售夥伴加入我們不斷增長的網絡。"
INBS' first-of-its-kind solution uses fingerprint sweat to provide a quick, hygienic, and easy-to-use method for drug testing, delivering results in just minutes. This unique approach tests for common drugs of abuse, including cocaine, cannabis, methamphetamine, and opiates.
INBS 的首個解決方案採用指紋汗液提供快速、衛生、易於使用的毒品測試方法,只需幾分鐘即可得到結果。這種獨特的方法測試常見的藥物濫用,包括可卡因、大麻、甲基苯丙胺和鴉片類藥物。
About Intelligent Bio Solutions Inc.
關於Intelligent Bio Solutions公司。
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company's biosensor platform has the potential to test for various indications, ranging from immunological conditions to communicable diseases. The Company's current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
Intelligent Bio Solutions Inc.(納斯達克股票代碼:INBS)是一家醫療技術公司,提供創新、快速、非侵入性的測試解決方案。該公司認爲,其Intelligent Fingerprinting Drug Screening System通過指紋汗液分析將革命化便攜式測試,這在其他領域有廣泛的應用潛力。該測試設計爲衛生和成本效益系統,針對工作場所常見藥物的近期使用進行篩查,包括鴉片、可卡因、甲基苯丙胺和大麻。該技術不到十分鐘即可完成樣本採集和結果分析,對於安全重要的行業僱主來說,這是有價值的工具。此外,該公司的生物傳感器平台還有可能測試各種指標,從免疫病症到傳染性疾病。該公司的當前客戶群包括建築、製造和工程、運輸物流公司、藥物治療組織和驗屍官。
For more information, visit:
請訪問:
Forward-Looking Statements:
前瞻性聲明:
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
本發佈中的某些聲明屬於屬於1933年證券法第27A條、1934年證券交易法第21E條和1995年私人證券訴訟法改革法案規定的前瞻性聲明,其中包括風險和不確定性。本新聞稿中的前瞻性聲明包括但不限於Intelligent Bio Solutions Inc.成功開發和商業化其藥物和診斷測試、從其合作和協議中實現商業利益以及獲得監管批准等。雖然Intelligent Bio Solutions Inc.認爲其所作出的前瞻性聲明在其做出之日是合理的,在市場發生情況後,預期可能與此前瞻性聲明所表達的結果有實質性不同。Intelligent Bio Solutions Inc.已試圖通過特定術語識別前瞻性聲明,包括“相信”、“預計”、“預估”、“預測”、“打算”、“計劃”、“項目”、“意圖”、“潛力”、“可能”、“可能性”、“將”、“應”、“大約”或其他表達不確定未來事件或結果的詞語以識別這些前瞻性聲明。這些聲明僅爲預測,涉及已知和未知的風險、不確定性和其他因素,該公司公開文件已提交證券交易委員會。本次發佈中包含的任何前瞻性聲明僅於發佈日期有效。Intelligent Bio Solutions Inc.不承擔更新本發佈中包含的任何前瞻性聲明以反映之後事件或情況或反映未預期事件的任何責任。
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
公司聯繫方式:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | 推特
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
投資者及媒體聯繫方式:
Lisa Miller
Lumos Pharma投資者 Relations
512-792-5454
ir@lumos-pharma.com
來源:Lumos Pharma, Inc。
Valter Pinto, 董事總經理
KCSA戰略傳播
電話:(212)896-1254
INBS@kcsa.com